$174 Million is the total value of Stonepine Capital Management, LLC's 30 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $23,189,000 | +301.8% | 1,260,288 | +470.7% | 13.34% | +163.2% |
| AMRN | Sell | AMARIN CORP PLC -ADRspons adr new | $19,647,000 | +31.2% | 946,379 | -14.0% | 11.30% | -14.0% |
| LGND | New | LIGAND PHARMACEUTICALS | $18,857,000 | – | 150,000 | +100.0% | 10.85% | – |
| NEOS | Buy | NEOS THERAPEUTICS INC | $11,775,000 | +69.5% | 4,511,504 | +7.2% | 6.77% | +11.0% |
| APEN | Buy | APOLLO ENDOSURGERY INC | $9,651,000 | +28.0% | 2,580,518 | +18.1% | 5.55% | -16.2% |
| BDSI | Sell | BIODELIVERY SCIENCES INTL | $8,159,000 | -44.6% | 1,539,437 | -61.3% | 4.69% | -63.7% |
| HTGM | Buy | HTG MOLECULAR DIAGNOSTICS | $7,089,000 | +4.3% | 2,835,786 | +6.0% | 4.08% | -31.7% |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $6,999,000 | – | 984,329 | +100.0% | 4.03% | – |
| CPIX | Sell | CUMBERLAND PHARMACEUTICALS | $6,983,000 | -11.8% | 1,201,975 | -8.5% | 4.02% | -42.3% |
| ALIM | Sell | ALIMERA SCIENCES INC | $6,873,000 | +46.2% | 6,483,610 | -1.0% | 3.95% | -4.3% |
| New | AEGERION PHARMACEUTICALSAEGR 2 08/15/19note 2.000% 8/1 | $6,032,000 | – | 9,000,000 | +100.0% | 3.47% | – | |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $5,811,000 | – | 60,840 | +100.0% | 3.34% | – |
| OPHT | Buy | OPHTHOTECH CORP | $5,746,000 | +17.6% | 4,074,944 | +0.1% | 3.30% | -23.0% |
| CTIC | Sell | CTI BIOPHARMA CORP | $3,881,000 | -7.6% | 4,000,000 | -30.2% | 2.23% | -39.5% |
| OPNT | Sell | OPIANT PHARMACEUTICALS INC | $3,869,000 | -25.2% | 294,894 | -17.6% | 2.22% | -51.0% |
| APVO | New | APTEVO THERAPEUTICS INC | $3,505,000 | – | 3,894,219 | +100.0% | 2.02% | – |
| VIVE | Sell | VIVEVE MEDICAL INC | $3,199,000 | -10.9% | 3,403,402 | -0.4% | 1.84% | -41.6% |
| XOMA | New | XOMA CORP | $2,816,000 | – | 227,430 | +100.0% | 1.62% | – |
| FOMX | Sell | FOAMIX PHARMACEUTICALS LTD | $2,738,000 | -41.0% | 730,004 | -43.5% | 1.58% | -61.4% |
| EBS | New | EMERGENT BIOSOLUTIONS INC | $2,364,000 | – | 46,800 | +100.0% | 1.36% | – |
| OXFD | Sell | OXFORD IMMUNOTEC GLOBAL PLC | $2,192,000 | -22.8% | 127,224 | -42.8% | 1.26% | -49.5% |
| MTNB | New | MATINAS BIOPHARMA HOLDINGS I | $2,189,000 | – | 2,008,006 | +100.0% | 1.26% | – |
| AFMD | Sell | AFFIMED NV | $2,124,000 | -4.4% | 505,736 | -29.2% | 1.22% | -37.4% |
| CHMA | New | CHIASMA INC | $1,560,000 | – | 300,000 | +100.0% | 0.90% | – |
| VSTM | New | VERASTEM INC | $1,480,000 | – | 500,000 | +100.0% | 0.85% | – |
| IDXG | New | INTERPACE DIAGNOSTICS GROUP | $1,147,000 | – | 1,434,030 | +100.0% | 0.66% | – |
| DMAC | New | DIAMEDICA THERAPEUTICS INC | $1,135,000 | – | 250,000 | +100.0% | 0.65% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $1,004,000 | – | 98,860 | +100.0% | 0.58% | – |
| SBBP | New | STRONGBRIDGE BIOPHARMA PLC | $932,000 | – | 187,074 | +100.0% | 0.54% | – |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $909,000 | – | 60,045 | +100.0% | 0.52% | – |
| Exit | CATABASIS PHARMACEUTICALS IN | $0 | – | -41,688 | -100.0% | -0.16% | – | |
| NVLNF | Exit | NOVELION THERAPEUTICS INC | $0 | – | -531,662 | -100.0% | -0.39% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -114,710 | -100.0% | -0.41% | – |
| ATEC | Exit | ALPHATEC HOLDINGS INC | $0 | – | -338,278 | -100.0% | -0.68% | – |
| CEMI | Exit | CHEMBIO DIAGNOSTICS INC | $0 | – | -147,011 | -100.0% | -0.73% | – |
| CORV | Exit | CORREVIO PHARMA CORP | $0 | – | -424,101 | -100.0% | -0.93% | – |
| BSTC | Exit | BIOSPECIFICS TECHNOLOGIES | $0 | – | -217,395 | -100.0% | -11.57% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.